全球顶尖生物医药风投齐聚，首届S2S中国研讨会创业提案征集倒计时

Core Insights - The S2S China conference aims to connect groundbreaking scientific research from China with top global biopharmaceutical capital, focusing on early-stage projects that have not yet secured Series A funding or established legal entities [2][3]. Group 1: Event Overview - The first S2S China conference will be held on October 15, 2026, in Hangzhou, Zhejiang, co-hosted by RA Capital Management and Qiming Venture Partners [1]. - The proposal submission for the conference is open until March 1, 2026, targeting top universities and research institutions in China [1][3]. Group 2: Selection Criteria - S2S China is looking for breakthrough technologies in the concept validation stage, specifically those that are proprietary academic technologies in the treatment field [3]. - Ideal candidate projects should have a clinical application timeline of less than 4-5 years and possess key data support, demonstrating significant advantages over existing therapies [3]. Group 3: Mentorship and Networking - Unlike traditional roadshows, S2S employs a unique mentorship model, connecting selected scientists with venture capital mentors for one-on-one collaboration [3]. - Selected scientists will have opportunities to engage directly with top-tier investment firms, including RA Capital, Qiming Venture Partners, and others, to explore potential investment opportunities [3].